Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.

The seventh stock among the small-cap stocks is Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).

TheFly reported on February 27 that Wells Fargo reduced its price target on AMPH to $30 from $34 and kept an Overweight rating on the shares. Despite the recent approvals of AMP-015 and AMP-007, the firm observes that the stock is under pressure because of the reduced sales projection. According to the firm, AMP-007's performance is anticipated to be crucial in attaining mid-to high-single-digit revenue growth in the future.

In a recent development, the FDA approved Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)'s Abbreviated New Drug Application (ANDA) for Ipratropium Bromide HFA Inhalation Aerosol, 17 mcg per actuation, on February 26. The FDA found that AMPH's product is medically and bioequivalent to Atrovent HFA Inhalation Aerosol from Boehringer Ingelheim.

For this inhalation aerosol, AMPH is entitled to 180 days of generic exclusivity since it is the first ANDA applicant to receive a Paragraph IV certification. The first day of the product's commercial introduction will mark the start of this exclusivity period, giving AMPH a brief window of market protection.

In addition to supporting the company's Q4 2025 earnings report, the approval is a major regulatory milestone that puts it in a position to increase its market share in the respiratory medication industry while utilizing the advantages of exclusivity to spur early product uptake.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a biopharmaceutical company that develops, manufactures, and markets injectable, inhalation, and intranasal medications, including complex generics and proprietary products, for hospitals and clinical use. Its portfolio addresses critical care needs and drug delivery innovations.

While we acknowledge the potential of AMPH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best GARP Stocks to Buy According to Analysts and 14 Best Affordable Dividend Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.